Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10494526 | 0.82 | KMT2A (0.44) | KMT2AGAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2434424 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TSHRTDP1CYP2A6 | |
| SCHEMBL23555163 | 0.74 | CCR5 (0.39) | KMT2AGAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23638850 | 0.74 | S100A4 (0.46) | TP53LMNACYP2A6 | |
| SCHEMBL30598347 | 0.74 | S100A4 (0.46) | TP53LMNACYP2A6 | |
| SCHEMBL530450 | 0.73 | — | — | |
| SCHEMBL29443091 | 0.73 | — | — | |
| SCHEMBL6692254 | 0.71 | MAP2K2 (0.30) | — | |
| SCHEMBL979334 | 0.71 | DGAT1 (0.41) | KMT2AGAATP53ALDH1A1ALOX15 | |
| SCHEMBL9837348 | 0.71 | FSCN1 (0.40) | KMT2ATP53FSCN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-6747175-B2 | EXCHANGING A CHLORINE ATOM AND A FLUORINE ATOM IN A BENZYL POSITION; RING CHLORINATION | RHODIA CHIMIE (FR) | 2004-06-08 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-20030130542-A1 | Chlorination of an aniline in a hydrofluoric medium | RHODIA CHIMIE (FR) | 2003-07-10 | — | — | US | disclosed |
| EP-1259476-A1 | CHLORINATION OF AN ANILINE IN ORTHO IN A HYDROFLUORIC MEDIUM | RHODIA CHIMIE (FR) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064623-A1 | CHLORINATION OF AN ANILINE IN ORTHO IN A HYDROFLUORIC MEDIUM | RHODIA CHIMIE (FR) | 2001-09-07 | — | — | WO | disclosed |
| US-3960890-A | CONTROL OF ECTOPARASITES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | KMT2A 1453/4885GAA 2113/4885SLC6A2 2962/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | KMT2A 2546/4885GAA 1144/4885SLC6A2 4464/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | KMT2A 3485/4885GAA 4788/4885SLC6A2 3338/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | KMT2A 3179/4885GAA 4849/4885SLC6A2 3616/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | KMT2A 3693/4885GAA 4486/4885SLC6A2 3759/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | KMT2A 3485/4885GAA 4788/4885SLC6A2 3338/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | KMT2A 1453/4885GAA 2113/4885SLC6A2 2962/4885 |
| US-20030130542-A1 | Chlorination of an aniline in a hydrofluoric medium | PEX3, PHF13, ATL3 | KMT2A 1891/4885GAA 3519/4885SLC6A2 876/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | KMT2A 3461/4885GAA 4829/4885SLC6A2 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.